Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Periodicals
ALLSTAR study data shows benefit in heart attack survivors, Cedars Sinai says » 10:54
08/04/20
08/04
10:54
08/04/20
10:54
CAPR

Capricor Therapeutics

$7.92 /

+0.24 (+3.13%)

Data from the ALLSTAR…

Data from the ALLSTAR study published by the European Heart Journal showed that although infusions of allogeneic cardiac cells - called cardiosphere-derived cells or CDCs - did not appear to shrink the scar left on heart muscle after a heart attack, other data from the study show a clear benefit, according to a post in the newsroom of Cedar Sinai. "The newly analyzed data from the ALLSTAR study, which was sponsored by Capricor Therapeutics, showed that patients given a placebo had hearts that continued to swell, holding larger volumes of blood, while the patients who received CDC infusions had smaller hearts with lower volumes," the report on the trial stated. Reference Link

ShowHide Related Items >><<
CAPR Capricor Therapeutics
$7.92 /

+0.24 (+3.13%)

CAPR Capricor Therapeutics
$7.92 /

+0.24 (+3.13%)

02/03/20 Maxim
Capricor Therapeutics upgraded to Buy from Hold at Maxim
CAPR Capricor Therapeutics
$7.92 /

+0.24 (+3.13%)

CAPR Capricor Therapeutics
$7.92 /

+0.24 (+3.13%)

Over a month ago
Conference/Events
Parent Project Muscular Dystrophy to hold a webinar » 12:55
06/03/20
06/03
12:55
06/03/20
12:55
CAPR

Capricor Therapeutics

$4.81 /

+0.01 (+0.21%)

Webinar entitled,…

Webinar entitled, "Capricor's HOPE -2 Final 12-Month Data" will be held on June 3 at 1 pm. Webcast Link

ShowHide Related Items >><<
CAPR Capricor Therapeutics
$4.81 /

+0.01 (+0.21%)

CAPR Capricor Therapeutics
$4.81 /

+0.01 (+0.21%)

02/03/20 Maxim
Capricor Therapeutics upgraded to Buy from Hold at Maxim
07/15/19 H.C. Wainwright
Capricor price target raised to $12.40 from $3.50 at H.C. Wainwright
CAPR Capricor Therapeutics
$4.81 /

+0.01 (+0.21%)

CAPR Capricor Therapeutics
$4.81 /

+0.01 (+0.21%)

Conference/Events
Parent Project Muscular Dystrophy to hold a webinar » 08:56
06/03/20
06/03
08:56
06/03/20
08:56
CAPR

Capricor Therapeutics

$4.80 /

-0.02 (-0.41%)

Webinar entitled,…

Webinar entitled, "Capricor's HOPE -2 Final 12-Month Data" will be held on June 3 at 1 pm. Webcast Link

ShowHide Related Items >><<
CAPR Capricor Therapeutics
$4.80 /

-0.02 (-0.41%)

CAPR Capricor Therapeutics
$4.80 /

-0.02 (-0.41%)

02/03/20 Maxim
Capricor Therapeutics upgraded to Buy from Hold at Maxim
07/15/19 H.C. Wainwright
Capricor price target raised to $12.40 from $3.50 at H.C. Wainwright
CAPR Capricor Therapeutics
$4.80 /

-0.02 (-0.41%)

CAPR Capricor Therapeutics
$4.80 /

-0.02 (-0.41%)

Conference/Events
Maxim Group to hold a virtual conference » 09:25
05/27/20
05/27
09:25
05/27/20
09:25
APDN

Applied DNA Sciences

$11.78 /

+0.69 (+6.22%)

, BIOC

Biocept

$0.50 /

-0.0041 (-0.82%)

, BNGO

Bionano Genomics

$0.50 /

+0.0322 (+6.87%)

, CAPR

Capricor Therapeutics

$5.26 /

-0.13 (-2.41%)

, CODX

Co-Diagnostics

$18.03 /

-0.57 (-3.06%)

, DXR

Daxor

$14.00 /

-0.03 (-0.21%)

, LCTX

Lineage Cell Therapeutics

$1.04 /

+0.1806 (+21.01%)

, MESO

Mesoblast

$12.95 /

+0.76 (+6.23%)

, PSTI

Pluristem

$7.97 /

-0.39 (-4.67%)

, VNRX

VolitionRx

$3.11 /

+0.12 (+4.01%)

Maxim Group Virtual…

Maxim Group Virtual COVID-19 Conference will be held on May 27.

ShowHide Related Items >><<
VNRX VolitionRx
$3.11 /

+0.12 (+4.01%)

PSTI Pluristem
$7.97 /

-0.39 (-4.67%)

MESO Mesoblast
$12.95 /

+0.76 (+6.23%)

LCTX Lineage Cell Therapeutics
$1.04 /

+0.1806 (+21.01%)

DXR Daxor
$14.00 /

-0.03 (-0.21%)

CODX Co-Diagnostics
$18.03 /

-0.57 (-3.06%)

CAPR Capricor Therapeutics
$5.26 /

-0.13 (-2.41%)

BNGO Bionano Genomics
$0.50 /

+0.0322 (+6.87%)

BIOC Biocept
$0.50 /

-0.0041 (-0.82%)

APDN Applied DNA Sciences
$11.78 /

+0.69 (+6.22%)

APDN Applied DNA Sciences
$11.78 /

+0.69 (+6.22%)

05/05/20 Maxim
Applied DNA Sciences price target raised to $18 from $8 at Maxim
11/22/19
Fly Intel: Top five analyst upgrades
11/22/19 Maxim
Applied DNA Sciences upgraded to Buy from Hold at Maxim
BIOC Biocept
$0.50 /

-0.0041 (-0.82%)

05/14/20 Brookline
Biocept initiated with a Buy at Brookline
BNGO Bionano Genomics
$0.50 /

+0.0322 (+6.87%)

04/08/20 Oppenheimer
Oppenheimer bullish on Bionano Genomics, initiates with an Outperform
04/08/20 Oppenheimer
Bionano Genomics initiated with an Outperform at Oppenheimer
CAPR Capricor Therapeutics
$5.26 /

-0.13 (-2.41%)

02/03/20 Maxim
Capricor Therapeutics upgraded to Buy from Hold at Maxim
07/15/19 H.C. Wainwright
Capricor price target raised to $12.40 from $3.50 at H.C. Wainwright
CODX Co-Diagnostics
$18.03 /

-0.57 (-3.06%)

05/20/20 Maxim
Co-Diagnostics upgraded to Buy from Hold at Maxim
05/20/20 Maxim
Co-Diagnostics upgraded to Buy from Hold at Maxim
05/18/20 H.C. Wainwright
Co-Diagnostics price target raised to $35 from $20 at H.C. Wainwright
03/09/20 H.C. Wainwright
Co-Diagnostics price target raised to $20 from $4 at H.C. Wainwright
DXR Daxor
$14.00 /

-0.03 (-0.21%)

09/30/19 Roth Capital
Daxor initiated with a Neutral at Roth Capital
07/29/19
Daxor initiated with a Buy at Maxim
07/29/19 Maxim
Daxor initiated with a Buy at Maxim
LCTX Lineage Cell Therapeutics
$1.04 /

+0.1806 (+21.01%)

05/06/20 H.C. Wainwright
Lineage update shows OpRegen 'nicely on track,' says H.C. Wainwright
MESO Mesoblast
$12.95 /

+0.76 (+6.23%)

04/09/20 H.C. Wainwright
H.C. Wainwright 'encouraged' by Mesoblast's plan to study Ryoncil in ARDS
10/22/19 Cantor Fitzgerald
Mesoblast assumed with an Overweight at Cantor Fitzgerald
09/10/19 Cantor Fitzgerald
Mesoblast partnership deal with Grunenthal a positive, says Cantor Fitzgerald
PSTI Pluristem
$7.97 /

-0.39 (-4.67%)

04/24/20 H.C. Wainwright
Pluristem removed overhang with loan agreement, says H.C. Wainwright
04/13/20 Maxim
Pluristem price target raised to $12 from $8 at Maxim
04/07/20 H.C. Wainwright
Early COVID-19 results 'a game changer' for Pluristem, says H.C. Wainwright
02/10/20 Dawson James
Pluristem could have 'blockbuster' therapy for CLI, says Dawson James
VNRX VolitionRx
$3.11 /

+0.12 (+4.01%)

05/06/20 Aegis
VolitionRx initiated with a Buy at Aegis
LCTX Lineage Cell Therapeutics
$1.04 /

+0.1806 (+21.01%)

CODX Co-Diagnostics
$18.03 /

-0.57 (-3.06%)

CAPR Capricor Therapeutics
$5.26 /

-0.13 (-2.41%)

BNGO Bionano Genomics
$0.50 /

+0.0322 (+6.87%)

CODX Co-Diagnostics
$18.03 /

-0.57 (-3.06%)

VNRX VolitionRx
$3.11 /

+0.12 (+4.01%)

MESO Mesoblast
$12.95 /

+0.76 (+6.23%)

CODX Co-Diagnostics
$18.03 /

-0.57 (-3.06%)

APDN Applied DNA Sciences
$11.78 /

+0.69 (+6.22%)

VNRX VolitionRx
$3.11 /

+0.12 (+4.01%)

PSTI Pluristem
$7.97 /

-0.39 (-4.67%)

MESO Mesoblast
$12.95 /

+0.76 (+6.23%)

CODX Co-Diagnostics
$18.03 /

-0.57 (-3.06%)

CAPR Capricor Therapeutics
$5.26 /

-0.13 (-2.41%)

Conference/Events
Capricor Therapeutics holds a pharmaceutical update conference call » 07:55
05/13/20
05/13
07:55
05/13/20
07:55
CAPR

Capricor Therapeutics

$7.84 /

-0.27 (-3.33%)

Management holds a…

Management holds a conference call to discuss the top-line results of the HOPE-2 Study will be held on May 13 at 8 am. Webcast Link

ShowHide Related Items >><<
CAPR Capricor Therapeutics
$7.84 /

-0.27 (-3.33%)

CAPR Capricor Therapeutics
$7.84 /

-0.27 (-3.33%)

02/03/20 Maxim
Capricor Therapeutics upgraded to Buy from Hold at Maxim
07/15/19 H.C. Wainwright
Capricor price target raised to $12.40 from $3.50 at H.C. Wainwright
CAPR Capricor Therapeutics
$7.84 /

-0.27 (-3.33%)

CAPR Capricor Therapeutics
$7.84 /

-0.27 (-3.33%)

Earnings
Capricor Therapeutics reports Q1 EPS (30c), two est. (33c)  07:23
05/13/20
05/13
07:23
05/13/20
07:23
CAPR

Capricor Therapeutics

$7.84 /

-0.27 (-3.33%)

 
ShowHide Related Items >><<
CAPR Capricor Therapeutics
$7.84 /

-0.27 (-3.33%)

CAPR Capricor Therapeutics
$7.84 /

-0.27 (-3.33%)

02/03/20 Maxim
Capricor Therapeutics upgraded to Buy from Hold at Maxim
07/15/19 H.C. Wainwright
Capricor price target raised to $12.40 from $3.50 at H.C. Wainwright
CAPR Capricor Therapeutics
$7.84 /

-0.27 (-3.33%)

CAPR Capricor Therapeutics
$7.84 /

-0.27 (-3.33%)

Hot Stocks
Capricor Therapeutics announces top-line results from HOPE-2 study » 07:23
05/13/20
05/13
07:23
05/13/20
07:23
CAPR

Capricor Therapeutics

$7.84 /

-0.27 (-3.33%)

Capricor Therapeutics…

Capricor Therapeutics announced positive top-line 12-month results of the HOPE-2 clinical trial using CAP-1002 to treat patients in advanced stages of Duchenne muscular dystrophy, a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. Boys and young men typically lose their ability to walk in their teens and generally die of cardiac or respiratory complications by the 3rd decade of life. The data showed improvements in upper limb, cardiac and respiratory function with p-values less than p&#61;0.05 in multiple measures. The 12-month data from HOPE-2 showed statistically meaningful improvements in the PUL 2.0 in CAP-1002 treated patients with a mean change of 2.4 points over placebo patients. With the exception of steroids, preservation of function in DMD is uncommon. The placebo patients declined consistent with natural history, but in the treated group, most patients were stable or improved throughout the one-year treatment period. The performance of the upper limb is a clinically validated measure that evaluates upper limb strength in patients who are generally non-ambulant. Retention of upper limb function is important for self-care and preservation of human dignity and has become a focus for physicians and advocates to find treatments to help these later stage patients. The FDA has suggested the use of the updated PUL 2.0 version as the primary efficacy endpoint in support of a Biologics License Application. The data also showed global improvements in cardiac function as measured by ejection fraction (p&#61;0.004) and indexed volumes. These are surrogate measures of cardiac function and are considered the "gold standard" in terms of relevance to long term outcomes. Remarkably, there is also a reduction in the biomarker CK-MB, an enzyme that is only released when there is cardiac muscle cell damage. In normal human subjects, there is typically no CK-MB measurable in the blood. It is well accepted that continuous muscle cell damage in DMD leads to pathologically high enzyme levels associated with cardiac muscle cell loss. HOPE-2 demonstrated a reduction in CK-MB levels as compared to placebo. This is the first ever study in DMD that correlates cardiac functional stabilization with reduction of a biomarker of cell damage. CAP-1002 was generally safe and well tolerated throughout the study. With the exception of hypersensitivity reactions which were mitigated with a common pre-medication regimen, no safety signals were identified in the HOPE-2 trial. The FDA has granted Capricor's CAP-1002 RMAT and Orphan Drug Designation, and the FDA has also granted a Rare Pediatric Disease Designation to CAP-1002 for DMD. The Rare Pediatric Disease Designation, as well as the Orphan Drug Designation previously granted, covers the broad treatment of DMD. If Capricor were to receive market approval for CAP-1002 by the FDA, Capricor would be eligible to receive a Priority Review Voucher. This is the second clinical trial investigating CAP-1002 showing similar results in DMD. Capricor completed the HOPE-Duchenne trial published in Neurology, the medical journal of the American Academy of Neurology in 2019. The Company has initiated a technology transfer with a leading global CMO to prepare for commercial manufacturing of CAP-1002.

ShowHide Related Items >><<
CAPR Capricor Therapeutics
$7.84 /

-0.27 (-3.33%)

CAPR Capricor Therapeutics
$7.84 /

-0.27 (-3.33%)

02/03/20 Maxim
Capricor Therapeutics upgraded to Buy from Hold at Maxim
07/15/19 H.C. Wainwright
Capricor price target raised to $12.40 from $3.50 at H.C. Wainwright
CAPR Capricor Therapeutics
$7.84 /

-0.27 (-3.33%)

CAPR Capricor Therapeutics
$7.84 /

-0.27 (-3.33%)

Syndicate
Capricor Therapeutics files to sell 4.2M shares of common stock for holders  17:26
05/07/20
05/07
17:26
05/07/20
17:26
CAPR

Capricor Therapeutics

$7.02 /

+0.235 (+3.46%)

 
ShowHide Related Items >><<
CAPR Capricor Therapeutics
$7.02 /

+0.235 (+3.46%)

02/03/20 Maxim
Capricor Therapeutics upgraded to Buy from Hold at Maxim
07/15/19 H.C. Wainwright
Capricor price target raised to $12.40 from $3.50 at H.C. Wainwright
Over a quarter ago
Options
Four new option listings and one option delisting on May 6th » 08:30
05/06/20
05/06
08:30
05/06/20
08:30
BNTX

BioNTech

$49.97 /

+4.41 (+9.68%)

, CAPR

Capricor Therapeutics

$6.86 /

-0.42 (-5.77%)

, NNA

Navios Acquisition

$5.22 /

-0.55 (-9.53%)

, TSG

The Stars Group

$27.28 /

+ (+0.00%)

New option listings for…

New option listings for May 6th include BioNTech SE (ADS) (BNTX), Capricor Therapeutics (CAPR), Navios Maritime Acquisition (NNA), and Flutter Entertainment PLC (PDYPF). Option delistings effective May 6th include Stars Group Inc (TSG).

ShowHide Related Items >><<
BNTX BioNTech
$49.97 /

+4.41 (+9.68%)

04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/13/20 H.C. Wainwright
BioNTech price target raised to $48 from $30 at H.C. Wainwright
04/03/20 Canaccord
BioNTech price target raised to $60 from $22 at Canaccord
CAPR Capricor Therapeutics
$6.86 /

-0.42 (-5.77%)

02/03/20 Maxim
Capricor Therapeutics upgraded to Buy from Hold at Maxim
07/15/19 H.C. Wainwright
Capricor price target raised to $12.40 from $3.50 at H.C. Wainwright
NNA Navios Acquisition
$5.22 /

-0.55 (-9.53%)

TSG The Stars Group
$27.28 /

+ (+0.00%)

04/21/20 Canaccord
The Stars Group price target raised to C$35.29 from C$30.65 at Canaccord
04/16/20 Redburn
The Stars Group upgraded to Buy from Neutral at Redburn
04/08/20 Susquehanna
The Stars Group upgraded to Positive from Neutral at Susquehanna
10/28/19 RBC Capital
The Stars Group initiated with an Outperform at RBC Capital
Hot Stocks
Capricor: Data reports 100% survival in COVID-19 patients treated with CAP-1002 » 09:18
04/29/20
04/29
09:18
04/29/20
09:18
CAPR

Capricor Therapeutics

$2.38 /

-0.09 (-3.64%)

Capricor Therapeutics…

Capricor Therapeutics announced new data reporting 100 percent survival in critical COVID-19 patients who were treated with Capricor's lead asset, off-the-shelf cardiac cell therapy CAP-1002, at Cedars-Sinai Medical Center as part of six compassionate care cases. Over the course of one month, six critically ill COVID-19 patients, all suffering from acute respiratory distress syndrome and five of whom were on mechanical ventilatory support, were safely treated with CAP-1002. Of the six patients treated, four of them have been discharged. Following a review of the available data, the U.S. Food and Drug Administration approved the Company's expanded access protocol to treat up to 20 additional COVID-19 patients. There is also a randomized, placebo-controlled trial planned to treat patients with moderate and severe disease which is intended to be funded by non-equity capital. In the compassionate care cases, five male patients and one female patient suffering from COVID-19 received IV infusions of 150 million allogeneic cardiosphere-derived cells. Of the five patients on ventilator support, four patients no longer required ventilator support within just one to four days following the infusion. The fifth patient remains on mechanical ventilation and the sixth patient is receiving supplemental oxygen and is currently clinically stable. Additionally, laboratory biomarkers correlated with poor outcomes were measured in all patients. Following infusion, several patients showed improvements in biomarkers, such as ferritin, absolute lymphocyte counts and CRP. No adverse events related to the administration of CAP-1002 were observed. This data has been submitted for publication. CAP-1002 demonstrates immunomodulatory properties. Multiple published peer-reviewed studies of CDCs have demonstrated favorable modulation of various inflammatory cytokines and regulation of the immune response. The current understanding of COVID-19's later stages are thought to be due to overstimulation of the immune system, which triggers a cytokine storm in which the body is overwhelmed with pro-inflammatory molecules. This immune response may become excessive and pathologic, inducing pneumonia, organ failure and death. Therefore, it can be the body's overreaction to COVID-19, rather than the virus itself, that delivers the fatal blow. Capricor is also in late-stage clinical development of CAP-1002 for Duchenne muscular dystrophy. In DMD, the lack of dystrophin produces abnormal inflammatory responses, which are responsible for much of the damage to skeletal and cardiac muscle. The Company has previously announced that top-line results of HOPE-2, a randomized, placebo-controlled study, will be released by mid-May 2020.

ShowHide Related Items >><<
CAPR Capricor Therapeutics
$2.38 /

-0.09 (-3.64%)

02/03/20 Maxim
Capricor Therapeutics upgraded to Buy from Hold at Maxim
07/15/19 H.C. Wainwright
Capricor price target raised to $12.40 from $3.50 at H.C. Wainwright

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.